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Abstract
Background: The oxidative modification of LDL is be-
lieved to be an initial step in atherosclerosis. Thus,
antioxidative substances such as carotenoids may have
a role in the prevention of coronary heart disease. We
examined the susceptibility of LDL to Cu2+ oxidation in
young adults before and after a single dose of ß-crypto-
xanthin. Methods: 1.3 mg of ß-cryptoxanthin was admin-
istered to 12 apparently healthy young volunteers. Six of
the volunteers received esters, the other six free ß-cryp-
toxanthin. The plasma concentration of ß-cryptoxanthin
and the susceptibility of LDL to copper-induced oxidation
ex vivo in terms of the duration of lag time were mea-
sured before and 12 h after ß-cryptoxanthin ingestion.
Results: A single dose of ß-cryptoxanthin significantly
increased the mean plasma ß-cryptoxanthin concentra-
tion and the mean cholesterol adjusted ß-cryptoxanthin
concentration by 117 and 133%, respectively. No effect
on the length of lag time was assessed. However, in LDL
isolated from plasma 12 h after ß-cryptoxanthin adminis-
tration the lengths of lag time correlated significantly
with the plasma ß-cryptoxanthin concentration and with
the cholesterol adjusted ß-cryptoxanthin levels. The lag
time did not differ significantly between volunteers who
received esters and those who received the same dosage
as free ß-cryptoxanthin. At both measuring points, smok-
ers, male volunteers and women using oral contracep-
tives tended to exhibit lower ß-cryptoxanthin concentra-
tions and lower cholesterol adjusted ß-cryptoxanthin
concentrations as well as increased LDL oxidizability
compared to nonsmokers and women not using oral
contraceptives. Conclusion: A single dose of ß-cryptox-
anthin does not enhance the duration of LDL lag time ex
vivo in healthy young subjects.
Copyright © 2004 S. Karger AG, Basel
Introduction
Oxidized lipoproteins may play an important role in
the pathogenesis of atherosclerosis. Chemically modified
LDL, but not native LDL, is able to induce the formation
of foam cells, initiating the process of plaque formation.
LDL oxidation is likely to be the most important form of
LDL modification in humans and is connected with the
conversion of polyunsaturated fatty acids to lipid perox-
ides, which easily decompose to products such as biologi-
cally active aldehydes [1, 2].
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Antioxidants have been shown to prevent LDL oxida-
tion in vitro and may have a protective effect against the
progression of atherosclerosis. The predominant antioxi-
dant in LDL is ·-tocopherol, other substances with poten-
tial antioxidant activity are Á-tocopherol, ubiquinol-10,
phytofluene and the carotenoids ß-carotene, ·-carotene,
lycopene, ß-cryptoxanthin and canthaxanthin [3]. Epide-
miologic data indicate that a high fruit and vegetable con-
sumption and a high intake of carotenoids may prevent
atherosclerosis [4–7] as well as cancer [8–10]. Further-
more, results of studies have shown protective effects of
ß-cryptoxanthin, a xanthophyll that occurs mainly in
papaya, apricot, tangerine, peach and red pepper. Higher
dietary intake or higher plasma levels of ß-cryptoxanthin
were associated with a lower risk of angina pectoris [11,
12], cancer [13–17] and hyperglycemia [18] or revealed an
inverse association with the total mortality [19]. Since a
comparative study of the serum concentrations of carote-
noids in five European countries has shown that the con-
centrations of the sum of xanthophylls (lutein, zeaxan-
thin, ß-cryptoxanthin) and of ß-cryptoxanthin alone were
higher in southern (Spain) compared to the northern
areas, these serum levels have been suggested as impor-
tant markers related to the healthy or protective effects of
the Mediterranean diet [20].
Effects of supplemental carotenoids on ex vivo LDL
oxidation are contradictory. Some authors found reduced
LDL oxidation after ß-carotene administration [21, 22],
whereas other studies reported no effect on LDL oxida-
tion [23, 24]. Less information is available on the effect of
carotenoids other than ß-carotene on the susceptibility of
LDL to oxidation. In a study with lycopene, 4 healthy sub-
jects received a single dose of 30 mg of lycopene. Post-
prandial LDL isolated 5 h after lycopene administration
exhibited a significantly reduced susceptibility to oxida-
tion by 21% [25]. However in elderly Irish adults, supple-
mentation with a carotene mixture or lycopene for 12
weeks had no effect on oxidative modification of LDL in
vitro [26]. In a short-term intervention study, a dietary
intake of 140 mg/day of lycopene by a group of nonsmok-
ing individuals significantly reduced the susceptibility of
LDL to oxidation, whereas an equivalent increase in lyco-
pene by a group of smokers showed no such effect [27].
Different dosages of astaxanthin in the diet led to a reduc-
tion of the LDL oxidation [28].
To date, data on the effect of ß-cryptoxanthin on LDL
susceptibility to oxidation is scarce. In one study no asso-
ciation between the LDL lag time and the LDL ß-cryptox-
anthin concentrations was found in middle-aged and
elderly female and male subjects fed different diets [29].
Studies have shown that atherosclerosis often is associat-
ed with the occurrence of small, dense LDL. Particle con-
tents of ß-cryptoxanthin and other carotenoids were
markedly reduced in this type of LDL (LDL5, d = 1.050 to
1.065 g/ml) [30]. Furthermore, significantly lower plasma
levels of ß-cryptoxanthin were shown in subjects with ele-
vated inflammatory markers, especially C-reactive pro-
tein which is associated to cardiovascular disease [31].
Reduced antioxidant levels may contribute to a lower
resistance of LDL to oxidation and thus enhance oxida-
tive LDL modification and atherosclerosis.
We originally designed a single-blind comparative
study in order to compare the biokinetics of esters and
free ß-cryptoxanthin, which are both found in natural
sources of ß-cryptoxanthin. The results of the original
study showed no significant difference in the biokinetics
of esters and free ß-cryptoxanthin. This indicates compar-
ative bioavailability of both free ß-cryptoxanthin and a
mixture of different ß-cryptoxanthin esters [32]. In this
study, we evaluated the effect of a single dose of 1.3 mg of
ß-cryptoxanthin on the copper induced LDL oxidation ex
vivo.
Subjects, Methods and Materials
Subjects
Twelve subjects, 6 females, 6 males, were randomly assigned to
two groups. Among them 4 were smokers, the others were non-smok-
ers. Three of the females used oral contraceptives. None of the per-
sons suffered from gastrointestinal diseases, or took laxatives or
drugs lowering plasma triacylglycerol or cholesterol levels. They were
advised to take no supplements containing carotenoids or vitamins
in the 8 weeks before the study and during the intervention. The vol-
unteers were requested to keep a normal diet but to avoid ß-crypto-
xanthin-rich fruits and vegetables [32]. The study protocol was
approved by the Medical Ethics Committee of the Medizinische
Hochschule, Hannover, and the participants provided written in-
formed consent.
Study Design 
We investigated the effect of a single dose of esters and free ß-
cryptoxanthin on LDL susceptibility to oxidation ex vivo before (t0)
and 12 h after application of ß-cryptoxanthin (t1). The absolute
amount present in the diet was set to 1.3 mg ß-cryptoxanthin, corre-
sponding to a serving size of about 100 g native papaya. Thus, a phys-
iological dose of total ß-cryptoxanthin was administered to the vol-
unteers. The volunteers were instructed not to consume any fruits,
vegetables or products made from fruits and vegetables including
juices on the 24-hour intervention period. As previously described
[32], carotenoid application was performed by mixing a serving of
150 g yogurt with 4 g of spiked sunflower oil, resulting in a total
amount of 1.3 mg ß-cryptoxanthin, independent of the free or esteri-
fied form. The yogurt was consumed together with a standardized
breakfast with a total of approximately 24 g fat. Blood samples were
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collected before (0 h) and 12 h after ß-cryptoxanthin application. We
used the plasma samples taken 12 h after the ingestion of the ß-cryp-
toxanthin dose, because an elevated LDL ß-cryptoxanthin concentra-
tion could be expected at that time. Wingerath et al. [33] found the
peak levels of ß-cryptoxanthin in chylomicrons 6 h after ingestion of
a tangerine concentrate and our biokinetic study showed the highest
plasma concentrations at the measure points 9 and 12 h after the
ß-cryptoxanthin enriched breakfast [32]. Free and esterified ß-cryp-
toxanthin were prepared as previously described [32].
Plasma Sample Preparation and LDL Oxidation Measurement 
At both blood withdrawals, a volume of 9 ml was sampled from
each participant. Immediately after collection, the plasma was sepa-
rated from the erythrocytes by centrifugation (5,000 rpm, 10 min)
and stored at –70°C in plastic caps. From half of the plasma sample
the plasma ß-cryptoxanthin concentrations had been measured by
HPLC as described previously [32, 34, 35]. Total plasma triacylglyce-
rol and total cholesterol were measured manually by using commer-
cial in vitro enzymatic test kits. From the other half of the plasma,
LDL was isolated by an ultracentrifugation method based on non-
equilibrium density-gradient ultracentrifugation. For centrifugation
a 70Ti rotor (Beckman Optima LE-80K, Beckman Instruments, Palo
Alto, Calif., USA) was used. Centrifugation was carried out in poly-
carbonate centrifuge tubes at 288,000 g for 2 h at 15°C. The LDL
containing fraction was collected by aspiration. Salts and EDTA were
removed from LDL by gel filtration on Pharmacia PD 10 disposable
columns (Amersham Pharmacia Biotech, Freiburg, Germany). Once
the LDL was isolated, it was used immediately with no storage.
The ex vivo oxidation of LDL was performed after adding CuCl2
to a final concentration of 20 Ìmol/L based on a method previously
described [36]. Conjugated diene absorption was measured spectro-
photometrically at 234 nm every 5 min for 4 h. As a measure of the
susceptibility of LDL to oxidation the lag time was used. This has
been assessed from the time-absorption curve and is the time interval
between the intercept of the linear last square slope of the curve with
the initial-absorbance axis [36, 37].
Statistics 
Results are expressed as mean values B SDs. Normal distribu-
tion of data was checked using the Kolmogorov-Smirnov test. Since
the data showed a normal distribution, the t test for paired samples
was used to evaluate for differences between values of the same sam-
ple at two time points, before (t0) and after (t1) application of ß-
cryptoxanthin. The independent-sample t-test was used to reveal sig-
nificant differences in the plasma concentrations and the lag times
between the two groups (receiving free or esters of ß-cryptoxanthin)
and between smokers and non-smokers and male and female volun-
teers. Pearson correlation coefficients were calculated in order to
evaluate an association between the lag time and the plasma concen-
tration of ß-cryptoxanthin. p ! 0.05 was considered statistically sig-
nificant. All statistics were performed with SPSS 11.0 (SPSS Inc.,
Chicago, Ill., USA).
Results
The characteristics of the study population are shown
in table 1. Since carotenoids are transported in associa-
tion with lipoproteins, plasma triacylglycerol and choles-
Table 1. Characteristics of the volunteers (mean B SD)
Value (n = 12)
Age, years
BMI, kg/m2
Fasting plasma concentrations
27.3B5.7
24.5B3.0
Total cholesterol, mmol/L
Triacylglycerol, mmol/L
4.51B0.87
1.09B0.58
terol concentrations are highly correlated with circulating
carotenoid concentrations [38]. In fasting plasma, total
cholesterol correlated significantly with ß-cryptoxanthin
(r = 0.656, p = 0.021) in our sample, but there was no
significant association with plasma triacylglycerol. Thus,
plasma ß-cryptoxanthin concentrations are also indicated
as adjusted values for total cholesterol (Ìmol ß-cryptoxan-
thin/mmol total cholesterol).
The mean lag time measured in LDL from fasting plas-
ma before application of ß-cryptoxanthin was lower than
that in LDL from plasma taken 12 h after a single dose of
ß-cryptoxanthin, indicating a higher resistance to oxida-
tion after 12 h (table 2). However, the difference was
small and not statistically significant. No significant dif-
ferences in lag time, ß-cryptoxanthin concentration, cho-
lesterol adjusted ß-cryptoxanthin concentration at any
time point were seen between the volunteers who received
free ß-cryptoxanthin and those who received the esters.
At the measurement 12 h after ß-cryptoxanthin intake,
the LDL lag time of the total sample correlated signifi-
cantly with the ß-cryptoxanthin plasma concentration (r =
0.654, p = 0.021) and with the cholesterol adjusted ß-cryp-
toxanthin plasma concentration (r = 0.780, p = 0.003)
(fig. 1). This association was not seen if only the volun-
teers who received the ester were considered. However, in
volunteers who received free ß-cryptoxanthin, cholesterol
adjusted ß-cryptoxanthin plasma concentration corre-
lated significantly with the lag time, both measured 12 h
after ß-cryptoxanthin ingestion (t1) (r = 0.865, p =
0.026).
At both time points, men, smokers and women who
used oral contraceptives had lower mean ß-cryptoxanthin
concentrations and a lower mean lag-time than women,
nonsmokers, and women not using oral contraceptives,
respectively. However, these differences were not statisti-
cally significant (table 2).
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Table 2. Length of the lag phase and ß-cryptoxanthin plasma concentrations before (t0) and after (t1) ingestion of 1.3 mg ß-cryptoxanthin
(mean values B SD)
Lag phase
t0, min
Lag phase
t1, min
ß-Cryptoxanthin
t0, Ìmol/L
ß-Cryptoxanthin
t1, Ìmol/L
ß-Cryptoxanthin
t0, Ìmol/mmol
cholesterol
ß-Cryptoxanthin
t1, Ìmol/mmol
cholesterol
Total sample (n = 12) 74.3B10.3 75.5B11.1 0.06B0.05 0.13B0.081 0.012B0.009 0.028B0.0161
Group receiving free ß-cryptoxanthin (n = 6) 76.9B12.1 76.9B13.0 0.05B0.04 0.11B0.012 0.011B0.008 0.027B0.0173
Group receiving ß-cryptoxanthin esters (n = 6) 71.6B8.5 74.2B9.9 0.07B0.07 0.14B0.104 0.013B0.011 0.029B0.0155
Women (n = 6) 76.7B14.0 78.7B14.6 0.07B0.07 0.16B0.116 0.014B0.011 0.033B0.0207
Men (n = 6) 71.9B5.0 72.3B6.02 0.05B0.04 0.10B0.048 0.010B0.008 0.024B0.0099
Non-smokers (n = 8) 75.5B11.2 77.3B12.6 0.08B0.06 0.16B0.0810 0.015B0.010 0.033B0.01511
Smokers (n = 4) 71.9B9.2 72.1B7.7 0.03B0.02 0.07B0.05 0.006B0.004 0.019B0.013
Women not using oral contraceptives (n = 3) 84.3B11.6 86.4B15.9 0.11B0.08 0.22B0.092 0.021B0.011 0.045B0.017
Women using oral contraceptives (n = 3) 69.0B13.5 71.1B10.1 0.03B0.03 0.09B0.08 0.007B0.006 0.020B0.016
1 Significantly different from t0 (p ! 0.001, paired t test). 7 Significantly different from t0 (p = 0.014, paired t test).
2 Significantly different from t0 (p = 0.029, paired t test). 8 Significantly different from t0 (p = 0.013, paired t test).
3 Significantly different from t0 (p = 0.04, paired t test). 9 Significantly different from t0 (p = 0.016, paired t test).
4 Significantly different from t0 (p = 0.004, paired t test). 10 Significantly different from t0 (p = 0.001, paired t test).
5 Significantly different from t0 (p = 0.003, paired t test). 11 Significantly different from t0 (p = 0.002, paired t test).
6 Significantly different from t0 (p = 0.007, paired t test).
Fig. 1. Correlation between the duration of LDL lag time and the
cholesterol adjusted ß-cryptoxanthin concentrations 12 h after inges-
tion of 1.3 mg ß-cryptoxanthin.
Discussion
In this study we evaluated the effect of a single dose of
free or esterified ß-cryptoxanthin on the LDL susceptibili-
ty to ex vivo oxidation. All participants were instructed to
consume a low-carotenoid diet two weeks before and dur-
ing the intervention. The mean baseline concentration of
ß-cryptoxanthin was well below the usually observed con-
centration in human plasma and demonstrated the effect
of the depletion phase before beginning the intervention.
Both total triacylglycerol and cholesterol levels were in the
normal range for all subjects of both groups [32].
Since subjects who received esters and those who
received free ß-cryptoxanthin did not differ either in ß-
cryptoxanthin plasma concentrations or in cholesterol ad-
justed ß-cryptoxanthin plasma concentrations, or LDL
lag times, the results could be considered for the total
sample. After ß-cryptoxanthin application the plasma
ß-cryptoxanthin concentration increased significantly,
whereas the mean length of lag time was elevated margin-
ally by only !2%, which was not significant.
The results of previous studies evaluating the effect of
carotenoids on the susceptibility of LDL to oxidation are
inconsistent. In a study with apparently healthy adults
who either received a low-vegetable diet, a high-vegetable
diet or a low-vegetable diet with a carotenoid supplement
for 4 weeks, no significant effect on the ex vivo LDL oxi-
dation lag time was observed in any of the three interven-
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tion groups [39]. Other authors assessed the LDL oxida-
tion by human endothelial cells in culture and observed
no correlation with the carotenoid but with the tocopherol
content of LDL [40].
In contrast, Lowe and coworkers reported a strong pos-
itive correlation between total carotenoid plasma concen-
trations and the lag time of Cu2+-mediated oxidation [41].
This result had also been found earlier by an investigation
showing significantly enhanced resistance of LDL to oxi-
dation after 2 weeks of increased fruit and vegetable con-
sumption in smokers and nonsmokers of 14 and 28%,
respectively [42]. According to previous results [29], we
observed no significant correlation between the LDL lag
time and the plasma ß-cryptoxanthin concentrations be-
fore ß-cryptoxanthin administration. In contrast, the lag
time 12 h after ß-cryptoxanthin application correlated sig-
nificantly with both the plasma ß-cryptoxanthin concen-
trations as well as the cholesterol adjusted ß-cryptoxan-
thin concentrations. This correlation was even stronger, if
only volunteers who received free ß-cryptoxanthin were
considered. Since the participants were advised not to eat
any vegetables or fruits or products from vegetables or
fruits during the 24-hour intervention period, they had no
intake of typical antioxidants from vegetable sources.
Therefore ß-cryptoxanthin might have exhibited an effect
on the lag time. Though, we cannot exclude that other
substances of the diet such as vitamin E had an influence
on the lag time.
Hininger et al. [42] observed significantly lower plas-
ma ß-cryptoxanthin concentrations in smokers than in
nonsmokers. This corresponds to recent results [43–45]
and is confirmed by a tendency of lower ß-cryptoxanthin
concentrations in smokers than in nonsmokers in our
sample. Hininger et al. [42] found 30% higher baseline
ß-cryptoxanthin concentrations in nonsmokers than in
smokers. The smokers in our sample exhibited a 63% low-
er mean baseline concentration than nonsmokers, but
probably due to the small number of subjects the differ-
ence was not significant. Furthermore, we observed a ten-
dency of lower ß-cryptoxanthin concentrations in the
plasma of males compared to females. This agrees with
recent results from a Japanese study. In this investigation
plasma carotenoids had been investigated in 158 Japa-
nese men and women in relationship to their smoking
habits. Plasma levels of ß-cryptoxanthin were significant-
ly lower in males than in females and were significantly
lower in males who were current smokers, compared to
non-smokers [46].
Conclusion
A single dose of ß-cryptoxanthin significantly increases
the plasma ß-cryptoxanthin concentration and leads to a
significant correlation between the plasma concentration
and the LDL lag time 12 h after ß-cryptoxanthin inges-
tion. However, a physiological dose of ß-cryptoxanthin
does not induce a significant reduction of the susceptibili-
ty of LDL to copper-induced oxidation.
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